The ROE as of September 2024 (TTM) for Outlook Therapeutics, Inc. (OTLK) is 146.56%

According to Outlook Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 146.56%. This represents a change of 249.02% compared to the average of 41.99% of the last 4 quarters.

Outlook Therapeutics, Inc. (OTLK) Historical ROE (quarterly & annually)

How has OTLK ROE performed in the past?

The mean historical ROE of Outlook Therapeutics, Inc. over the last ten years is -80.50%. The current 146.56% ROE has changed -282.05% with respect to the historical average. Over the past ten years (40 quarters), OTLK's ROE was at its highest in in the June 2023 quarter at 375.70%. The ROE was at its lowest in in the June 2016 quarter at -1428.38%.

Outlook Therapeutics, Inc. (OTLK) ROE by Quarter and Year

Discovering the peaks and valleys of Outlook Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Outlook Therapeutics, Inc. (OTLK) Average ROE

How has OTLK ROE performed in the past?

The current ROE of Outlook Therapeutics, Inc. (OTLK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Outlook Therapeutics, Inc. (OTLK) ROE vs. Peers

How is OTLK’s ROE compared to its peers?

Outlook Therapeutics, Inc.’s ROE is less than Checkpoint Therapeutics, Inc. (292.43%), less than Mustang Bio, Inc. (1.40%), less than Reviva Pharmaceuticals Holdings, Inc. (7.96%), greater than Fortress Biotech, Inc. (-226.63%), greater than Kodiak Sciences Inc. (-77.23%), greater than Ocuphire Pharma, Inc. (-30.19%), greater than Protalix BioTherapeutics, Inc. (-45.15%), greater than EyePoint Pharmaceuticals, Inc. (-43.24%), greater than SELLAS Life Sciences Group, Inc. (-17349.62%), greater than Eyenovia, Inc. (-615.55%), greater than Cidara Therapeutics, Inc. (-401.89%), greater than Fortress Biotech, Inc. (-226.63%), less than Selecta Biosciences, Inc. (67.13%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Inozyme Pharma, Inc. (-68.93%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than HOOKIPA Pharma Inc. (-51.77%), less than Heron Therapeutics, Inc. (144.24%), less than Galera Therapeutics, Inc. (21.95%),

Build a custom stock screener for Outlook Therapeutics, Inc. (OTLK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Outlook Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Outlook Therapeutics, Inc. (OTLK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Outlook Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.